Investing.comQwen · 实盘不做把握 2/10不做原因:标的无直接敞口
北京时间·🕒 发布 14:04:40·⟳ 抓取 14:05:38 +58s·⚡ 决策 08-27 14:10:08 +4m30s·61.0 天前
安进与阿斯利康宣布Tezspire治疗嗜酸性食管炎III期CROSSING试验达到双主要终点
Tezspire治疗EoE的III期阳性结果对安进(市值$2380亿)和阿斯利康(市值$2580亿)的短线股价无实质增量：EoE患者池仅47万人(约半数一线治疗失败)，峰值销售乐观估计$5-15亿，占两家公司市值均<0.6%；且Dupixent已获批用于EoE构成先发竞争；事件仍处于topline阶段距商业化尚远。超大市值+小适应症+已有竞品=无可交易edge。
📄 原文Investing.com↗ 原文
Amgen, AstraZeneca report positive phase 3 trial for Tezspire in EoE
Nvidia Q2 earnings blow past estimates, sees 70% annual revenue growth THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) and…
不做 安进（AMGN.US）
超大市值($2380亿)软催化：EoE峰值销售<$15亿占市值<0.6%，Dupixent已获批构成先发竞争，III期topline不改变短期收入/指引，无短线交易edge
不做 阿斯利康（AZN.US）
超大市值($2580亿)软催化：同上逻辑，且股价近13周持续下行(13周轨迹100→93)，无支撑，正面小催化不足以扭转趋势
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Tezspire III期EoE试验达到终点是科学上正面消息，但量级核查显示：美国EoE患者47万、约半数一线无效→可触达~23万患者，按生物制剂年费$3-4万、渗透率30-50%估算峰值销售$5-15亿，占安进/阿斯利康市值均<0.6%。Dupixent 2022年已获批EoE适应症构成先发优势。对两家超大市值公司而言，这仅是管线期权增值，不改变短期收入/利润/指引，无短线交易edge。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
消息传播链
- Investing.com快讯报道，基于公司新闻稿；非一手源(原文标注AI辅助生成)，但内容与Amgen/阿斯利康官方PR一致市场反应:美股尚未开盘(盘前)，暂无反应
反向证据
- 做多前查反向 · 来源 web · 影响 invalidates
Dupixent(度普利尤单抗)2022年5月已获FDA批准用于12岁及以上EoE患者，Tezspire进入已有竞品市场，先发优势显著削弱增量
检索:Tezspire EoE竞争格局 Dupixent已获批
先例如何影响了这次决策
对本次决策的影响:先例不足不改变结论：materiality计算已独立证明事件对超大市值标的无短线交易价值
方向:无高相似先例可用
涨幅量级:无
形态:无
工具调用 · 历史记录,结果未知(5 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- web_search · 结果未知
- stock_quote · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 2,027 字
Nvidia Q2 earnings blow past estimates, sees 70% annual revenue growth
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) and AstraZeneca announced today positive results from a Phase 3 trial evaluating Tezspire (tezepelumab-ekko) for treatment of eosinophilic esophagitis, according to a press release statement.
The CROSSING trial met its co-primary endpoints at week 24, measuring histologic remission and dysphagia symptom improvement, with results sustained through week 52. The trial enrolled 368 patients aged 12-80 years with symptomatic and histologically active eosinophilic esophagitis who were randomized to receive either low or high dose Tezspire or placebo subcutaneously every four weeks.
Histologic remission was defined as a peak esophageal eosinophil count of six or fewer eosinophils per high-power field. Dysphagia symptoms were measured using the Dysphagia Symptom Questionnaire. Patients were permitted to continue background medications including proton pump inhibitors and swallowed topical corticosteroids during the trial.
The safety profile was consistent with Tezspire’s approved indications for severe asthma and chronic rhinosinusitis with nasal polyps. Tezspire is currently approved in the U.S., EU, China, Japan and more than 70 countries for severe asthma treatment, and in the U.S., EU, China and Japan for chronic rhinosinusitis with nasal polyps.
Eosinophilic esophagitis affects more than 470,000 people in the U.S., with prevalence increasing five-fold since 2009. The chronic inflammatory disorder causes difficulty swallowing, food impaction and esophageal narrowing. Nearly half of patients do not achieve adequate disease control with current first-line treatments.
Full trial results will be presented at an upcoming medical meeting and shared with regulatory authorities. Amgen and AstraZeneca share global costs, profits and losses equally under their collaboration agreement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) and AstraZeneca announced today positive results from a Phase 3 trial evaluating Tezspire (tezepelumab-ekko) for treatment of eosinophilic esophagitis, according to a press release statement.
The CROSSING trial met its co-primary endpoints at week 24, measuring histologic remission and dysphagia symptom improvement, with results sustained through week 52. The trial enrolled 368 patients aged 12-80 years with symptomatic and histologically active eosinophilic esophagitis who were randomized to receive either low or high dose Tezspire or placebo subcutaneously every four weeks.
Histologic remission was defined as a peak esophageal eosinophil count of six or fewer eosinophils per high-power field. Dysphagia symptoms were measured using the Dysphagia Symptom Questionnaire. Patients were permitted to continue background medications including proton pump inhibitors and swallowed topical corticosteroids during the trial.
The safety profile was consistent with Tezspire’s approved indications for severe asthma and chronic rhinosinusitis with nasal polyps. Tezspire is currently approved in the U.S., EU, China, Japan and more than 70 countries for severe asthma treatment, and in the U.S., EU, China and Japan for chronic rhinosinusitis with nasal polyps.
Eosinophilic esophagitis affects more than 470,000 people in the U.S., with prevalence increasing five-fold since 2009. The chronic inflammatory disorder causes difficulty swallowing, food impaction and esophageal narrowing. Nearly half of patients do not achieve adequate disease control with current first-line treatments.
Full trial results will be presented at an upcoming medical meeting and shared with regulatory authorities. Amgen and AstraZeneca share global costs, profits and losses equally under their collaboration agreement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。